AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31955480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined online and face-to-face continuing medical education (CME) programme
Number of subjects: 58
Study 31955480 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 doctors from three provinces)
Number of subjects: 58
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Attractive applicants
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral applicants
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese applicants
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Preclinical class rank
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical clerkship grades
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha Omega Alpha membership
Number of subjects: 74
Study 31149924 — intervention group
Group type: EXPERIMENTAL
Intervention: United States Medical Licensing Examination Step 1 scores
Number of subjects: 74
Study 27965377 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 264
Study 27965377 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study 25847934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab plus androgen deprivation (AD)
Number of subjects: 210
Study 25847934 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation (AD) alone
Number of subjects: 210
Study 25847934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cixutumumab plus AD
Number of subjects: 210
Study 23831322 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (qHPV)
Number of subjects: 0
Study 21661410 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐butyl‐2‐cyanoacrylate injection
Number of subjects: 43
Study 21661410 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation
Number of subjects: 43
Study 19751517 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physiotherapy sessions
Number of subjects: 174
Study 19751517 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy sessions
Number of subjects: 174
Study 16650669 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival sodium hyaluronate 2.3%
Number of subjects: 55
Study 16650669 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 55
Study 15611216 — intervention group
Group type: EXPERIMENTAL
Intervention: BACE intervention
Number of subjects: 78
Study 15611216 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 78
Study 11740831 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended cardiac evaluations
Number of subjects: 153
Study 11740831 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Blocker therapy
Number of subjects: 153
Study 11740831 — intervention group
Group type: COMPARATOR
Intervention: Invasive intervention for CAD
Number of subjects: 153
Study 10426663 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA (1250 mg/m2 daily x 5 every 4 weeks)
Number of subjects: 73
Study 10426663 — intervention group
Group type: COMPARATOR
Intervention: SAM (streptozotocin 400 mg/m2 IV daily x 5, doxorubicin 45 mg/m2 IV on day 1 and 22, methyl CCNU 60 mg/m2 orally on days 1 and 22 every 6 weeks)
Number of subjects: 73
Study 8017464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 423
Study 8017464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/day
Number of subjects: 423
Study 8017464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 2689478 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test
Number of subjects: 167
Study 2689478 — intervention group
Group type: COMPARATOR
Intervention: Finn Chamber
Number of subjects: 167
Study 2689478 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test and Finn Chamber
Number of subjects: 167
Study 2689478 — intervention group
Group type: EXPERIMENTAL
Intervention: History prediction
Number of subjects: 167
Study 2689478 — intervention group
Group type: EXPERIMENTAL
Intervention: Past or present relevance
Number of subjects: 167
Study 31791939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain review service
Number of subjects: 34
Study 31023751 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 89
Study 28077151 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategic intervention to increase implementation of a state‐wide healthy canteen policy
Number of subjects: 70
Study 28077151 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 70
Study 25812255 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion intervention for CVD prevention among persons with SMI
Number of subjects: 0
Study 25812255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in participation
Number of subjects: 0
Study 23936377 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exposure to moderate altitude (2590 m)
Number of subjects: 51
Study 22044858 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI
Number of subjects: 461
Study 18073312 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 7 days
Number of subjects: 18
Study 18073312 — intervention group
Group type: COMPARATOR
Intervention: Energy balance group (control)
Number of subjects: 18
Study 16939848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (300 mg twice a day)
Number of subjects: 32
Study 16939848 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without vitamin E supplementation (Control)
Number of subjects: 32
Study 12930195 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-training group (RT; n = 20)
Number of subjects: 39
Study 12930195 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; n = 19)
Number of subjects: 39
Study 11916175 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg orally three times per day for 7 days)
Number of subjects: 39
Study 11916175 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (1 g orally as a single dose)
Number of subjects: 39
Study 9611062 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16 positive
Number of subjects: 28
Study 9611062 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-18 positive
Number of subjects: 28
Study 9611062 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HPV-16 and HPV-18 positive
Number of subjects: 28
Study 8072200 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (400 mg Tegafur plus 896 mg uracil/day)
Number of subjects: 56
Study 8072200 — intervention group
Group type: COMPARATOR
Intervention: FT (800 mg/day)
Number of subjects: 56
Study 8072200 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT
Number of subjects: 56
Study 8072200 — intervention group
Group type: COMPARATOR
Intervention: FT
Number of subjects: 56
Study 8072200 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT and FT
Number of subjects: 56
Study 3178506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4.5 g n‐3 PUFA's)
Number of subjects: 14
Study 3178506 — intervention group
Group type: COMPARATOR
Intervention: Control (same oil, n‐6 PUFA's)
Number of subjects: 14
Study 31929213 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent film (nasal protective film)
Number of subjects: 46
Study 31929213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no transparent film)
Number of subjects: 46
Study 30616614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 200 mg plus febuxostat
Number of subjects: 196
Study 30616614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg plus febuxostat
Number of subjects: 196
Study 30616614 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat 80 mg (Control)
Number of subjects: 196
Study 29273063 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitrous Oxide (N2O) for 1 hour
Number of subjects: 0
Study 29273063 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (SSRI) after N2O administration
Number of subjects: 0
Study 29273063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air) for 1 hour
Number of subjects: 0
Study 27004412 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography
Number of subjects: 160
Study 27004412 — intervention group
Group type: COMPARATOR
Intervention: Conventional mean arterial pressure
Number of subjects: 160
Study 25739248 — intervention group
Group type: EXPERIMENTAL
Intervention: Paperboard and pad fixation
Number of subjects: 59
Study 25739248 — intervention group
Group type: COMPARATOR
Intervention: Short leg plaster
Number of subjects: 59
Study 23063399 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 73
Study 23063399 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 73
Study 19462722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine 50 mg
Number of subjects: 100
Study 19462722 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% 5 mL periprostatic infiltration
Number of subjects: 100
Study 19462722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 17846258 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 91
Study 17846258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 15103312 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan treatment
Number of subjects: 560
Study 15103312 — intervention group
Group type: COMPARATOR
Intervention: atenolol treatment
Number of subjects: 560
Study 15103312 — intervention group
Group type: EXPERIMENTAL
Intervention: older patients
Number of subjects: 560
Study 12270853 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg followed by 75 mg daily)
Number of subjects: 12562
Study 10331998 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital heart disease group awaiting surgery
Number of subjects: 3
Study 10331998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation group
Number of subjects: 3
Study 10331998 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison group
Number of subjects: 3
Study 7887658 — intervention group
Group type: EXPERIMENTAL
Intervention: Color slides
Number of subjects: 180
Study 7887658 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital images
Number of subjects: 180
Study 7887658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine specific skin conditions
Number of subjects: 180
Study 2403998 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day for 5 weeks
Number of subjects: 108
Study 2403998 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day for an additional 5 weeks
Number of subjects: 108
Study 45702 — intervention group
Group type: EXPERIMENTAL
Intervention: HALFD method (hypertonic albuminated fluid demand regimen)
Number of subjects: 0
Study 45702 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic fluid and Ringer's lactate resuscitation
Number of subjects: 0
Study 31590702 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous co-amoxiclav (1 g of amoxicillin/200 mg of clavulanic acid)
Number of subjects: 3427
Study 31590702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 3427
Study 28192003 — intervention group
Group type: EXPERIMENTAL
Intervention: WEBCARE (online, 12-weeks fixed, 6 lesson behavioral treatment based on problem solving therapy)
Number of subjects: 289
Study 28192003 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 289
Study 25630516 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus casei Shirota)
Number of subjects: 17
Study 25630516 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 17
Study 23412642 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 12054
Study 23412642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12054
Study 21252084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1% drops four times daily for 1 week
Number of subjects: 111
Study 21252084 — intervention group
Group type: COMPARATOR
Intervention: Hypromellose 0.3% drops four times daily for 1 week
Number of subjects: 111
Study 19585395 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER with paroxetine
Number of subjects: 0
Study 19585395 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine alone
Number of subjects: 0
Study 17762658 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 391
Study 17762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 391
Study 17762658 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 640 mg
Number of subjects: 391
Study 15626317 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft tissue punch technique with deproteinized bovine bone mineral integrated in a 10% collagen matrix and free gingival graft from the palate.
Number of subjects: 20
Study 11488790 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 76
Study 11488790 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 76
Study 9530612 — intervention group
Group type: EXPERIMENTAL
Intervention: DR‐70 immunoassay kit
Number of subjects: 413
Study 9391542 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg intravenously before chemotherapy)
Number of subjects: 97
Study 9391542 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (8 mg intravenously before chemotherapy, then every 8 hours for a total of 3 doses, plus 8 mg oral maintenance every 12 hours for 5 days)
Number of subjects: 97
Study 9391542 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 97
Study 9391542 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 97
Study 1895978 — intervention group
Group type: EXPERIMENTAL
Intervention: High osmolality contrast
Number of subjects: 884
Study 1895978 — intervention group
Group type: EXPERIMENTAL
Intervention: Low osmolality contrast
Number of subjects: 884
Study 1895978 — intervention group
Group type: COMPARATOR
Intervention: No contrast (plain scan)
Number of subjects: 884
Study 7119949 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU vitamin D/day
Number of subjects: 0
Study 7119949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU vitamin D/day
Number of subjects: 0
Study 7119949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7119949 — intervention group
Group type: COMPARATOR
Intervention: 400 IU vitamin D/day (control group for infants)
Number of subjects: 0
Study 29911353 — intervention group
Group type: EXPERIMENTAL
Intervention: Enlarged pegboard for Braille learning
Number of subjects: 68
Study 29911353 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Braille
Number of subjects: 68
Study 29911353 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually presented Braille characters (enlarged)
Number of subjects: 68
Study 29911353 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually presented Braille characters (standard size)
Number of subjects: 68
Study 29911353 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-specific tactile training)
Number of subjects: 68
Study 29911353 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tactile Braille
Number of subjects: 68
Study 28645254 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-collected vaginal HPV DNA specimens
Number of subjects: 150
Study 28645254 — intervention group
Group type: COMPARATOR
Intervention: Provider-collected cervical HPV swabs
Number of subjects: 150
Study 27836874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT) activated
Number of subjects: 200
Study 27836874 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronisation therapy (CRT) not activated
Number of subjects: 200
Study 25574983 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline nebulization
Number of subjects: 71
Study 25574983 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline nebulization
Number of subjects: 71
Study 21907959 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod
Number of subjects: 56
Study 21907959 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study 19966323 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 36
Study 19966323 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 36
Study 18985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of contempt
Number of subjects: 0
Study 18985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial expressions of disgust
Number of subjects: 0
Study 18985147 — intervention group
Group type: EXPERIMENTAL
Intervention: Male contemptuous faces
Number of subjects: 0
Study 18985147 — intervention group
Group type: COMPARATOR
Intervention: Contempt versus disgust
Number of subjects: 0
Study 16182772 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (n = 22)
Number of subjects: 47
Study 16182772 — intervention group
Group type: COMPARATOR
Intervention: Prograf (n = 25)
Number of subjects: 47
Study 12634969 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-metomidate PET imaging in group A (patients free of medication)
Number of subjects: 11
Study 12634969 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-metomidate PET imaging in group B (patients on medication)
Number of subjects: 11
Study 12634969 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-metomidate PET imaging
Number of subjects: 11
Study 12634969 — intervention group
Group type: COMPARATOR
Intervention: Medication with adrenal steroid inhibitors and chemotherapy
Number of subjects: 11
Study 10563615 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 0
Study 10563615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9087160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 micrograms aqueous nasal spray, administered twice daily for 2 weeks)
Number of subjects: 22
Study 9087160 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered twice daily for 2 weeks)
Number of subjects: 22
Study 9087160 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Number of subjects: 22
Study 1332022 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence intervention (Health Behavior in Cancer Prevention Model-based)
Number of subjects: 110
Study 1332022 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber group
Number of subjects: 110
Study 1332022 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 3842544 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium water (bottled from the low sodium community distribution system with no sodium added)
Number of subjects: 0
Study 3842544 — intervention group
Group type: COMPARATOR
Intervention: High sodium water (bottled from their own community distribution system)
Number of subjects: 0
Study 3842544 — intervention group
Group type: COMPARATOR
Intervention: Low sodium water (bottled from the comparison community with sodium added to the level of the high sodium community water)
Number of subjects: 0
Study 30706571 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs157582 in TOMM40 gene
Number of subjects: 2857
Study 30706571 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs (APOE: rs405509, rs439401; TOMM40: rs8106922; KIBRA: rs4320284, rs11740112, rs10040267, rs13171394, rs6555802, rs2241368, rs244904, rs6555805, rs10475878)
Number of subjects: 2857
Study 30706571 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs (COMT rs737865, BDNF rs1491850)
Number of subjects: 2857
Study 29871565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicolumnar arthrodesis
Number of subjects: 12
Study 29871565 — intervention group
Group type: COMPARATOR
Intervention: Radioscapholunate arthrodesis
Number of subjects: 12
Study 27571238 — intervention group
Group type: EXPERIMENTAL
Intervention: EquiaFil with Equia Coat
Number of subjects: 54
Study 27571238 — intervention group
Group type: COMPARATOR
Intervention: Riva SC with Fuji Varnish
Number of subjects: 54
Study 27571238 — intervention group
Group type: EXPERIMENTAL
Intervention: EquiaFil
Number of subjects: 54
Study 27571238 — intervention group
Group type: COMPARATOR
Intervention: Riva SC
Number of subjects: 54
Study 24738835 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperQuant
Number of subjects: 135
Study 24738835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrio
Number of subjects: 135
Study 24738835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrio Plus
Number of subjects: 135
Study 24738835 — intervention group
Group type: EXPERIMENTAL
Intervention: MPX
Number of subjects: 135
Study 24738835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrio Plus and MPX
Number of subjects: 135
Study 24738835 — intervention group
Group type: EXPERIMENTAL
Intervention: At least two assays
Number of subjects: 135
Study 22309881 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive dental intervention
Number of subjects: 141
Study 22309881 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 141
Study 19640359 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 0
Study 19640359 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 17636088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 116
Study 17636088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 116
Study 17636088 — intervention group
Group type: COMPARATOR
Intervention: Control (no CBT)
Number of subjects: 116
Study 17636088 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoxetine)
Number of subjects: 116
Study 15732870 — intervention group
Group type: EXPERIMENTAL
Intervention: BDX mixed with PRP
Number of subjects: 13